Enzyme replacement therapy (ERT) with recombinant human GLA enzyme (Agalsidase-α or Agalsidase-β) improves the clinical signs and symptoms of FD, such as kidney dysfunction, neuropathic pain, gastrointestinal disorders, and cardiac manifestations; the treatment reduces Lyso-Gb3 accumulation and delays organ damage (Biegstraaten et al., 2015). The gene discussed is GLA; the disease is digestive system disorder.